Zobrazeno 101 - 110
of 114
pro vyhledávání: '"John Scholler"'
Autor:
Decheng Song, John Scholler, Michael Klichinsky, Saar Gill, David L. Porter, Olga Shestova, Saad S. Kenderian, Carl H. June, Marco Ruella, Martin Carroll
Publikováno v:
Cancer Research. 75:3139-3139
Allogeneic stem cell transplantation is the only option in relapsed acute myeloid leukemia (AML). However, patients are often excluded due to refractory disease. The successful translation of Chimeric Antigen Receptor (CAR) T cell therapy to AML woul
Autor:
James Monslow, Diana Avery, Amy C. Durham, Ellen Puré, David J. Bajor, Steven M. Albelda, Liang-Chuan S. Wang, Carl H. June, John Scholler, Elizabeth L. Buza, Albert C. Lo, Robert H. Vonderheide, Rebecca A. Evans
Publikováno v:
Cancer Research. 75:3187-3187
Solid tumors recruit and activate a heterogeneous population of non-transformed stromal cells (CASCs) in the tumor microenvironment (TME). There has been growing interest in the field to develop strategies to treat cancer and circumvent resistance to
Autor:
Stephan A. Grupp, David L. Porter, J. Joseph Melenhorst, Michael Kalos, Ted J. Hofmann, Carl H. June, Farzana Nazimuddin, Saad S. Kenderian, Marco Ruella, David M. Barrett, John Scholler, Saar Gill, Olga Shestova, Simon F. Lacey
Publikováno v:
Blood. 124:966-966
Relapsing/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) is associated with a poor prognosis in both pediatric and adult patients. Novel therapies targeting CD19 on leukemic blasts, such as anti-CD19 Chimeric Antigen Receptor T cells (CAR
Autor:
Mariusz A. Wasik, Taylor Chen, John Scholler, Saar Gill, Saad S. Kenderian, Carl H. June, Marco Ruella, Olga Shestova
Publikováno v:
Blood. 124:806-806
Hodgkin lymphoma (HL) generally carries a good prognosis. However, 10-15% of patients relapse or are refractory to first-line therapy. These patients have a poor prognosis and would benefit from innovative approaches. Our group and others have demons
Autor:
Omkar U. Kawalekar, Sonia Guedan, Joseph A. Fraietta, Avery D. Posey, Roddy S. O’Connor, Michael C. Milone, Carl H. June, John Scholler
Publikováno v:
Blood. 124:551-551
BACKGROUND Chimeric antigen receptors (CARs) redirect T cells to recognize tumor cells, providing a powerful new approach to cancer immunotherapy. However, the attributes of CARs that ensure optimal in vivo tumor destruction and persistence of the CA
Autor:
Rick Sorensen, John Scholler, Charles Rauch, Daniel Branstetter, William C. Fanslow, Zhi Liu, Raymond M. Koelling, Jonathan M.J. Derry, Michael R. Comeau, Richard S. Johnson, Peter Robert Baum, Laurent J. Galibert, Thierry Walzer, Geoffrey S. Diemer, Jeffrey Smith, Wei Yan, Martin F. Wolfson, Anne-Renee Van Der Vuurst De Vries
Publikováno v:
The Journal of biological chemistry. 280(23)
Dendritic cells (DCs) are a phenotypically and functionally heterogenous population of leukocytes with distinct subsets serving a different set of specialized immune functions. Here we applied an in vitro whole cell panning approach using antibody ph
Autor:
John Scholler, Martin Carroll, David L. Porter, S. Grupp, Michael Kalos, S. Gill, Carl H. June, Sarah K. Tasian
Publikováno v:
Cytotherapy. 15:S13-S14
Autor:
Stephan A. Grupp, Olga Shestova, Simon F. Lacey, John Scholler, David M. Barrett, Michael Kalos, Carl H. June, Saad S. Kenderian, S. Gill, Marco Ruella
Publikováno v:
Cytotherapy. 16:S8
patients before or immediately after mCTL infusion. In the absence of conventional therapy, 8 of the 11 patients with CMV infection became negative for CMV in the blood within 7d of mCTL infusion, with a coinciding rise in CMV-specific CTL in PB. Eac
Autor:
Marco Ruella, Sarah K. Tasian, Olga Shestova, John Scholler, Saar Gill, Stephan A. Grupp, David L. Porter, Yong Li, Michael Kalos, Gwenn Danet-Desnoyers, Martin Carroll, Carl H. June
Publikováno v:
Blood. 122:143-143
Engineering of T cells with chimeric antigen receptors (CARs) can impart novel T cell specificity for an antigen of choice, and anti-CD19 CAR T cells have been shown to effectively eradicate CD19+ malignancies. Most patients with acute myeloid leukem
Autor:
Sonia Guedan, Carmine Carpenito, Xi Chen, Aviv Madar, Shannon McGettigan, Matthew Frigault, John Scholler, Nathalie Scholler, Richard Bonneau, Carl June
Publikováno v:
The Journal of Immunology. 190:177.8-177.8
Adoptive transfer of TH17 cells polarized and expanded in vitro is an attractive therapy for the treatment of cancer. CD278, the inducible costimulator (ICOS) has been shown to be critical for the sustained expansion of human TH17 cells after their p